Henagliflozin 10 mg daily + Metformin 1700 mg daily
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metabolic Dysfunction-associated Steatotic Liver Disease
Conditions
Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
Trial Timeline
Dec 31, 2024 → Dec 31, 2026
NCT ID
NCT06762223About Henagliflozin 10 mg daily + Metformin 1700 mg daily
Henagliflozin 10 mg daily + Metformin 1700 mg daily is a approved stage product being developed by Jiangsu Hengrui Medicine for Metabolic Dysfunction-associated Steatotic Liver Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06762223. Target conditions include Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus.
What happened to similar drugs?
18 of 20 similar drugs in Metabolic Dysfunction-associated Steatotic Liver Disease were approved
Approved (18) Terminated (4) Active (2)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06762223 | Approved | Recruiting |
Competing Products
20 competing products in Metabolic Dysfunction-associated Steatotic Liver Disease